ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2500-Wollongong-Wollongong-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
44
trial(s) found.
NCT07851025
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (
TREVI-OC-02
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT07728188
Haem
Phase 3
Not yet recruiting
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM) (
M22-538
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT07589634
Haem
Phase 2
Recruiting
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (
TRI-Pro
)
anti-IL-6 monoclonal antibody
placebo
trispecific T-cell engager,BCMA/GPRC5D-targeting
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
2500 - Wollongong - Wollongong Hospital
NCT07545356
Advanced
Phase 1
Recruiting
A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors (
KIVU-305-01
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Wollongong Hospital
QLD
4999 - Unspecified - Clinical Trial Site QLD
NCT07492641
Advanced
Phase 3
Recruiting
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease (
KANDELA-302
)
CDK4/6 inhibitor
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT07455851
Haem
Phase 1 / Phase 2
Recruiting
A FIH Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
R17372-HM-2493
)
bispecific GPRC5D/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2031 - Randwick - Prince of Wales Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07291037
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (
TROPION-Lung17
)
anti-Trop2 antibody-drug conjugate
taxane
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
2217 - Kogarah - St George Hospital (WITHDRAWN)
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07284849
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (
INCA033890-303
)
anti-VEGF monoclonal antibody
bispecific TGFBR2/PD-1 antibody
Colorectal adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07259213
Radonc
Phase 1 / Phase 2
Recruiting
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-
RAD402
, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants With Castration-Resistant Prostate Cancer (CRPC)
Castrate-resistant prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07214779
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (
MAESTRA-2
)
CDK2 inhibitor
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)
2139 - Concord - Concord Repatriation General Hospital (COMPLETED)
2500 - Wollongong - Wollongong Hospital (COMPLETED)
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
NCT07211958
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation (
REVEAL-ND-NPM1
)
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2031 - Randwick - Prince of Wales Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Linear Clinical Research
NCT07197580
Radonc
Phase 3
Recruiting
A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) (
LUTEON
)
radioconjugate,CA9-targeting
Clear cell renal cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07190300
Paed
Phase 1 / Phase 2
Recruiting
TulmiSTAR-02
: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer
CYP17A1 inhibitor
EZH1/2 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-sensitive prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
2050 - Camperdown - Chris O'Brien Lifehouse (WITHDRAWN)
NCT06997497
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) (
1084-012
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colon adenocarcinoma
Rectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06960395
Advanced
Phase 1
Recruiting
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (
VIR-5525-V101
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,EGFR-targeting
Cancer
Cervical squamous cell carcinoma
Colorectal cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06896916
Haem
Phase 1
Recruiting
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (
M24-555
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06824155
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-
RAD202
, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients With Advanced Solid Tumours
radioconjugate,ERBB2-targeting
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06796907
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
anti-B7H4 antibody-drug conjugate
Cancer
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06768489
Haem
Phase 1
Recruiting
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalidomide for Multiple Myeloma (
79635322MMY1002
)
anti-CD38 monoclonal antibody
immunomodulatory imide drug
trispecific T-cell engager,BCMA/GPRC5D-targeting
AL amyloidosis
Amyloidosis
Multiple myeloma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
NCT06731478
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (
DS8201-724
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06692738
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02) (
D702BC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06669247
Haem
Phase 1 / Phase 2
Recruiting
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
COSTIMM
)
bispecific CD38/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06630806
Haem
Phase 1
Recruiting
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
TED18162
)
anti-GPRC5D monoclonal antibody
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06627647
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) (
D702FC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06613009
Advanced
Phase 1
Recruiting
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer (
CIBI3009A101
)
anti-DLL3 antibody-drug conjugate
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06520345
Radonc
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment (
177Lu-TLX591-203
)
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
Prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - Melbourne - Australian Prostate Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
WA
6150 - Murdoch - GenesisCare Murdoch
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06349408
Advanced
Phase 1
Recruiting
A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI3001A101
)
bispecific EGFR/B7H3 antibody-drug conjugate
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT06345079
Advanced
Phase 2
Recruiting
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (
STOPNET
)
Octreotide
cancer therapy
endocrine therapy
endocrine therapy,somastatin axis-targeting
somatostatin analog
Neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4350 - Toowoomba - Toowoomba Hospital
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
6430 - Kalgoorlie-Boulder - Kalgoorlie Health Campus
NCT06340568
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (
Fern-EC-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Endometrial cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06305962
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06233942
Advanced
Phase 1
Recruiting
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (
BG-C9074-101
)
anti-B7H4 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (COMPLETED)
NCT06106945
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma (
D7230C00001
)
anti-GPRC5D antibody-drug conjugate
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
Breast cancer
Epithelial Ovarian Cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
NCT05669989
Haem
Phase 2
Enrolling by invitation
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (
LTS17704
)
anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05533697
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (
mRNA-4359-P101
)
mRNA personalised cancer vaccine,IDO/PD-L1-targeting
Solid tumour
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2228 - Miranda - Southside Cancer Care Centre
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT04643002
Haem
Phase 1 / Phase 2
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
ACTRN12626000289314
Advanced
Phase 1
Recruiting
Part C: A Phase 1b, open-label, non-randomised, multicentre dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AXA-042 monotherapy in subjects with advanced solid tumours.
TLR2/TLR6 agonist
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3175 - Dandenong - Dandenong Hospital
SA
5037 - Glandore - Ashford Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12626000026325
Advanced
Not Applicable
Not yet recruiting
Evaluating the feasibility and acceptability of Geriatric Assessment-Driven Interventions for oncology patients at Wollongong Hospital (
GAIN-Woll
)
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
ACTRN12625000697482
Advanced
Phase 2
Recruiting
A parallel-group, 2-arm, Phase 2, multisite, stratified, double-blind, randomised, study to investigate the safety and effectiveness of doxycycline or placebo in conjunction with standard of care in adults with metastatic adenocarcinoma of the lung undergoing targeted anti-cancer therapy. (
DULCE
)
placebo
tetracycline antibiotic
Lung cancer
NT
0870 - Alice Springs, Alice Springs Hospital
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
NCT07885267
Advanced
Phase 1
Completed
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects With Advanced Solid Malignancies (
AT-0174-001
)
dual IDO/TDO inhibitor
Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2228 - Miranda - Southside Cancer Care Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05462236
Advanced
Phase 2
Unknown
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (38)
Not yet recruiting (2)
Enrolling by invitation (1)
Completed (1)
Unknown (1)
Recruitment Country and State
NSW (43)
VIC (30)
QLD (22)
WA (17)
SA (12)
NZ (3)
TAS (1)
ACT (1)
NT (1)
Phase
Phase 1 (12)
Phase 1 / Phase 2 (9)
Phase 2 (6)
Phase 3 (15)
Phase 4 (1)
Trial Type
Advanced (25)
Haem (13)
Radonc (5)
Paed (1)
Cancer Therapy Class
PD-1/PD-L1
27%
PD-1
23%
cereblon
16%
VEGF
14%
BCMA
14%
CD38
14%
EGFR
7%
ERBB2
7%
PD-L1
7%
GPRC5D
7%
proteasome
5%
CDK4
5%
CDK6
5%
oestrogen axis
5%
Trop2
5%
CDK2
5%
AR
5%
CYP17A1
5%
androgen axis
5%
B7H4
5%
CTLA4
5%
TIGIT
5%
IDO
5%
FR-alpha
2%
IL-6
2%
CEACAM5
2%
CDK4 selective
2%
TGFBR2
2%
KMT2A
2%
menin-MLL1
2%
menin
2%
EZH1
2%
EZH2
2%
KRAS
2%
CD28
2%
DLL3
2%
PSMA
2%
B7H3
2%
somastatin axis
2%
ER
2%
CD47
2%
IL-2
2%
ROCK2
2%
TGF-beta
2%
TLR2/TLR6
2%
DNA methyltransferase
2%
TDO
2%
MNK
2%
Facility
2500 - Wollongong - Wollongong Hospital (44)
3000 - Melbourne - Peter MacCallum Cancer Centre (10)
3065 - Fitzroy - St Vincent's Hospital Melbourne (9)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (7)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (7)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (6)
2031 - Randwick - Prince of Wales Hospital (5)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
3004 - Melbourne, Southbank - Alfred Health (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3168 - Clayton - Monash Medical Centre (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
3121 - Richmond - Epworth Freemasons Hospital (4)
4217 - Benowa - Pindara Private Hospital (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (4)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
4215 - Southport - Gold Coast University Hospital (4)
2109 - North Ryde - Macquarie University Hospital (4)
2170 - Liverpool - Liverpool Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
2217 - Kogarah - St George Hospital (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
4812 - Hyde Park - Icon Cancer Centre Townsville (3)
6150 - Murdoch - GenesisCare Murdoch (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
5000 - Adelaide - Cancer Research SA (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2139 - Concord - Concord Repatriation General Hospital (2)
6009 - Nedlands - One Clinical Research (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
2541 - Nowra - Shoalhaven District Memorial Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2228 - Miranda - Southside Cancer Care Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4999 - Unspecified - Clinical Trial Site QLD (1)
2605 - Garran - The Canberra Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
6009 - Nedlands - Hollywood Private Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
6000 - Perth - Royal Perth Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3051 - Melbourne - Australian Prostate Centre (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
NA
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
6430 - Kalgoorlie-Boulder - Kalgoorlie Health Campus (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3175 - Dandenong - Dandenong Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
0870 - Alice Springs, Alice Springs Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Thoracic cancer
Lung cancer
Respiratory tract cancer
Gynaecological cancer
Gastrointestinal cancer
Non-small cell lung cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Ovarian cancer
Breast cancer
Colorectal adenocarcinoma
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Epithelial Ovarian Cancer
Castrate-resistant prostate cancer
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Head and neck cancer
Head and neck squamous cell carcinoma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Endometrial cancer
Breast adenocarcinoma
Triple-negative breast cancer
Clear cell renal cell carcinoma
Kidney cancer
Castrate-sensitive prostate cancer
Colon adenocarcinoma
Rectal adenocarcinoma
Cervical cancer
Cervical squamous cell carcinoma
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
AL amyloidosis
Amyloidosis
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
Non-squamous non-small-cell lung cancer
Neuroendocrine tumour
Cutaneous melanoma
Melanoma
Skin cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary fallopian tube serous carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy